• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Akili Inc.

    2/12/24 2:22:56 PM ET
    $AKLI
    Medical/Dental Instruments
    Health Care
    Get the next $AKLI alert in real time by email
    SC 13G 1 formsc13g-02122024_070252.htm FORM schedule-13g


     
     


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13G
    Under the Securities Exchange Act of 1934


     
    Akili, Inc.
    (Name of Issuer)
    Common
    (Title of Class of Securities)
    00974B107
    (CUSIP Number)
    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [ x ] Rule 13d-1(b)

    [   ] Rule 13d-1(c)

    [   ] Rule 13d-1(d)



    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.


    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     
     


     
    CUSIP No. 00974B107
      (1)   

    Names of Reporting Persons/ I.R.S. Identification Nos. of Above Persons (Entities Only)

     

        Neuberger Berman Group LLC

        61-1591182

      (2)  
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a)  
    (b)   Membership in Group is Disclaimed
      (3)  

    SEC Use Only

     

      (4)  

    Citizenship or Place of Organization

     

        Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With

       (5)    

    Sole Voting Power

     

        0

       (6)   

    Shared Voting Power

     

        3466071

       (7)   

    Sole Dispositive Power

     

        0

       (8)   

    Shared Dispositive Power

     

        5776784

    (9)

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

        5776784

    (10)

     

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares   [   ]

     

        (See Instructions)

    (11)

     

    Percent of Class Represented by Amount in Row (9)

     

        7.38%

    (12)

     

    Type of Reporting Person (See Instructions)

     

        HC


    CUSIP No. 00974B107
      (1)   

    Names of Reporting Persons/ I.R.S. Identification Nos. of Above Persons (Entities Only)

     

        Neuberger Berman Investment Advisers LLC

        02-0654486

      (2)  
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a)  
    (b)   Membership in Group is Disclaimed
      (3)  

    SEC Use Only

     

      (4)  

    Citizenship or Place of Organization

     

        Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With

       (5)    

    Sole Voting Power

     

        0

       (6)   

    Shared Voting Power

     

        3466071

       (7)   

    Sole Dispositive Power

     

        0

       (8)   

    Shared Dispositive Power

     

        5776784

    (9)

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

        5776784

    (10)

     

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares   [   ]

     

        (See Instructions)

    (11)

     

    Percent of Class Represented by Amount in Row (9)

     

        7.38%

    (12)

     

    Type of Reporting Person (See Instructions)

     

        IA


    Item 1.
    (a) Name of Issuer
    Akili, Inc.
    (b) Address of Issuer's Principal Executive Offices
    71 COMMERCIAL STREET, MAILBOX 312
    BOSTON, Massachusetts, 02109

    Item 2.
    (a) Name of Person Filing
    Neuberger Berman Group LLC
    Neuberger Berman Investment Advisers LLC
    (b) Address of Principal Business Office or, if none, Residence
    1290 Avenue of the Americas
    New York, NY 10104
    (c) Citizenship
    Delaware
    (d) Title of Class of Securities
    Common
    (e) CUSIP Number
    00974B107

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)
    [   ]
    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)
    [   ]
    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)
    [   ]
    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)
    [   ]
    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
    (e)
    [   ]
    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
    (f)
    [   ]
    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
    (g)
    [   ]
    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)
    [   ]
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)
    [   ]
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)
    [ x ]
    Group, in accordance with §240.13d-1(b)(1)(ii)(J).

    Item 4.
    (a) Amount beneficially owned:
    5776784

    Neuberger Berman Trust Co N.A., Neuberger Berman Trust Co of Delaware N.A., Neuberger Berman Asia Ltd., Neuberger Berman Canada ULC, and Neuberger Berman Investment
    Advisers LLC and certain affiliated persons may be deemed to beneficially own the securities covered by this report in their various fiduciary capacities by virtue of the provisions of
    Exchange Act Rule 13d-3. Neuberger Berman Group LLC, through its subsidiaries Neuberger Berman Investment Advisers Holdings LLC and Neuberger Trust Holdings LLC controls
    Neuberger Berman Trust Co N.A., Neuberger Berman Asia Ltd., Neuberger Berman Canada ULC, Neuberger Berman Trust Co of Delaware N.A. and Neuberger Berman Investment
    Advisers LLC and certain affiliated persons.
    This report is not an admission that any of these entities are the beneficial owner of the securities covered by this report and each of Neuberger Berman Group LLC, Neuberger Berman
    Investment Advisers Holdings LLC, Neuberger Trust Holdings LLC, Neuberger Berman Trust Co N.A., Neuberger Berman Asia Ltd., Neuberger Berman Canada ULC, Neuberger Berman
    Trust Co of Delaware N.A. and Neuberger Berman Investment Advisers LLC and certain affiliated persons disclaim beneficial ownership of the securities covered by this statement pursuant
    to Exchange Act Rule 13d-4.
    The information in this filing reports securities of the issuer that may be deemed to be beneficially owned by Neuberger Berman Group LLC, Neuberger Berman Investment Advisers
    Holdings LLC, Neuberger Trust Holdings LLC, Neuberger Berman Trust Co N.A., Neuberger Berman Asia Ltd., Neuberger Berman Canada ULC, Neuberger Berman Trust Co of Delaware
    N.A. and Neuberger Berman Investment Advisers LLC ("NBG Filers"). The securities of the issuer, if any, that may be deemed to be beneficially owned by NB Alternatives Advisers LLC
    and other subsidiaries of Neuberger Berman Group LLC that are separated from the NBG Filers by an information barrier in accordance with SEC Release No. 34-39538 (January 12, 1998)
    are not reflected in this filing.
    (b) Percent of class:
    7.38%
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote
    0
    (ii) Shared power to vote or to direct the vote
    3466071
    (iii) Sole power to dispose or to direct the disposition of
    0
    (iv) Shared power to dispose or to direct the disposition of
    5776784

    Item 5. Ownership of Five Percent or Less of a Class
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [   ]

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
    Neuberger Berman Group LLC and its affiliates may be deemed to be beneficial owners of securities for purposes of Exchange Act Rule 13d-3 because they or certain affiliated persons have
    shared power to retain, dispose of or vote the securities of unrelated clients. Neuberger Berman Group LLC or its affiliated persons do not, however, have any economic interest in the securities of
    those clients. The clients have the sole right to receive and the power to direct the receipt of dividends from or proceeds from the sale of such securities. Other than named in this filing, no one
    client has an interest of more than 5% of the issuer.
    With regard to the shares set forth under item 4(c)(ii), Neuberger Berman Group LLC may be deemed to be the beneficial owner for purposes of Rule 13d-3 because certain affiliated persons have
    shared power to retain, dispose of and vote the securities. In addition to the holdings of individual advisory clients, Neuberger Berman Investment Advisers LLC serves as investment manager of
    Neuberger Berman Group LLC's various registered mutual funds which hold such shares. The holdings belonging to clients of Neuberger Berman Trust Co N.A., Neuberger Berman Trust Co of
    Delaware N.A., Neuberger Berman Asia Ltd., Neuberger Berman Canada ULC and Neuberger Berman Investment Advisers LLC are also aggregated to comprise the holdings referenced herein.
    In addition to the shares set forth under Item 4(c)(ii) for which Neuberger entities also have shared power to dispose of the shares, item 4(c)(iv) also includes shares from individual client accounts
    over which Neuberger Berman Investment Advisers LLC has shared power to dispose but does not have voting power over these shares. The holdings of Neuberger Berman Trust Co N.A.,
    Neuberger Berman Trust Co of Delaware N.A., Neuberger Berman Asia Ltd., Neuberger Berman Canada ULC and Neuberger Berman Investment Advisers LLC, are also aggregated to comprise
    the holdings referenced herein.

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.
    N/A

    Item 8. Identification and Classification of Members of the Group.
    N/A

    Item 9. Notice of Dissolution of Group.
    N/A

    Item 10. Certification.
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
     


     
    SIGNATURES
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
    Date:   February 12, 2024
    Neuberger Berman Group LLC
    By: /s/ Brad Cetron

    Name: Brad Cetron
    Title: Managing Director
    Date:   February 12, 2024
    Neuberger Berman Investment Advisers LLC
    By: /s/ Brad Cetron

    Name: Brad Cetron
    Title: Managing Director


    Get the next $AKLI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AKLI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AKLI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Akili Inc.

      SC 13D/A - Akili, Inc. (0001850266) (Subject)

      7/9/24 8:05:26 AM ET
      $AKLI
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Akili Inc.

      SC 13D/A - Akili, Inc. (0001850266) (Subject)

      7/5/24 5:36:11 PM ET
      $AKLI
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Akili Inc.

      SC 13G/A - Akili, Inc. (0001850266) (Subject)

      7/5/24 12:05:26 PM ET
      $AKLI
      Medical/Dental Instruments
      Health Care

    $AKLI
    Financials

    Live finance-specific insights

    See more
    • PureTech Health plc – Half-Year Report

      Strong progress across PureTech's portfolio, with significant near-term catalysts Robust shareholder returns enabled by Founded Entity1 monetization; $100 million Tender Offer and $50 million buyback completed Strong balance sheet with expected operational runway for at least three years Company to host a webcast and conference call today at 9:00am EDT / 2:00pm BST PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announces its half-yearly results for the six months ended June 30, 2024. The following information will be filed on Form 6-K w

      8/28/24 2:01:00 AM ET
      $AKLI
      $BMY
      $PRTC
      $VOR
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Akili Announces Amended Agreement with Shionogi, Shift in Corporate Strategy and Release Date for First Quarter 2024 Financial Results

      Shionogi amendment provides Akili with near-term cash payments and cancellation of debt obligation Company announces exploration of strategic alternatives and associated workforce reduction Company to release first quarter 2024 financial results on May 14, 2024 Akili, Inc. (NASDAQ:AKLI), a leading digital medicine company, today provided several corporate updates, including an amendment to its strategic distribution agreement with Shionogi & Co., Ltd. ("Shionogi"), a leading global pharmaceutical company. Under the terms of the amended agreement, Shionogi has canceled and forgiven a $5.0 million long-term debt obligation and agreed to make certain payments for SDT-001 (the Japanese, l

      4/30/24 8:00:00 AM ET
      $AKLI
      Medical/Dental Instruments
      Health Care
    • Akili Announces Release Date for Fourth Quarter and Full Year 2023 Financial Results, Provides Investor Communications and Board and Corporate Governance Updates

      Plans to disclose Q4/FY 2023 financial results on February 29, 2024; CEO Matthew Franklin to participate in fireside chat at TD Cowen's 44th Annual Healthcare Conference on March 4, 2024 Appointed John Spinale to Board of Directors and Audit Committee; provides update regarding plans for April 17, 2024 Annual Meeting and efforts to regain compliance with Nasdaq rules Akili, Inc. (NASDAQ:AKLI), a leading digital medicine company, today provided several corporate updates, including that it plans to report fourth quarter and full year 2023 financial results and a business update via press release on Thursday, February 29, 2024 after the market closes. The company will not be hosting an ear

      2/21/24 4:05:00 PM ET
      $AKLI
      Medical/Dental Instruments
      Health Care

    $AKLI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PureTech Health plc – Half-Year Report

      Strong progress across PureTech's portfolio, with significant near-term catalysts Robust shareholder returns enabled by Founded Entity1 monetization; $100 million Tender Offer and $50 million buyback completed Strong balance sheet with expected operational runway for at least three years Company to host a webcast and conference call today at 9:00am EDT / 2:00pm BST PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announces its half-yearly results for the six months ended June 30, 2024. The following information will be filed on Form 6-K w

      8/28/24 2:01:00 AM ET
      $AKLI
      $BMY
      $PRTC
      $VOR
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Virtual Therapeutics Announces Results of Tender Offer to Acquire Akili Interactive

      Virtual Therapeutics, a company focused on improving mental health at scale using engaging, immersive games ("Virtual Therapeutics"), today announced that it has successfully completed the tender offer commenced on June 3, 2024, to acquire all outstanding shares of common stock of Akili, Inc. (NASDAQ:AKLI) ("Akili") for $0.4340 per share (the "Offer Price"). The tender offer expired at one minute after 11:59 p.m. EDT on July 1, 2024 (the "Expiration Date"). As of the Expiration Date, a total of 69,674,538 shares, representing approximately 88.2% of the outstanding shares of common stock of Akili, were validly tendered and not validly withdrawn. The number of shares validly tendered in acc

      7/2/24 7:19:00 AM ET
      $AKLI
      Medical/Dental Instruments
      Health Care
    • Akili Announces FDA Authorization of EndeavorOTC, the First FDA Clearance of a Digital Treatment for Adults with ADHD Through a Video Game

      Clinically proven to improve attention function, EndeavorOTCⓇ is the first and only digital therapeutic cleared by FDA as an over-the-counter treatment for adults with ADHD Akili, Inc. (NASDAQ:AKLI), a leading digital therapeutics company, today announced U.S. Food and Drug Administration (FDA) clearance of EndeavorOTCⓇ (AKL-T01) as an over-the-counter treatment for adults with attention-deficit/hyperactivity disorder (ADHD). Delivered through an engaging video game experience, EndeavorOTC is indicated to improve attention function as measured by computer-based testing in men and women with primarily inattentive or combined-type ADHD, who have a demonstrated attention issue. EndeavorOTC i

      6/18/24 4:01:00 PM ET
      $AKLI
      Medical/Dental Instruments
      Health Care

    $AKLI
    Leadership Updates

    Live Leadership Updates

    See more
    • Akili Announces Leadership Transition

      Co-founder and CEO Eddie Martucci, Ph.D. transitions to role of Board chair; Matt Franklin, president and chief operating officer of Akili, appointed president and chief executive officer Akili, Inc. (NASDAQ:AKLI), a leading digital medicine company, today announced that Eddie Martucci transitioned to the role of Board chair, and Matt Franklin has been appointed to serve as president and CEO of the company and as a member of its board of directors, effective October 5, 2023. Martucci replaces former Board chair, Chamath Palihapitiya, who has resigned from the Board, effective October 4, 2023. The leadership transition follows the company's announcement in September that it plans to shif

      10/6/23 7:00:00 AM ET
      $AKLI
      Medical/Dental Instruments
      Health Care

    $AKLI
    SEC Filings

    See more
    • SEC Form 15-12G filed by Akili Inc.

      15-12G - Akili, Inc. (0001850266) (Filer)

      7/12/24 5:16:02 PM ET
      $AKLI
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by Akili Inc.

      EFFECT - Akili, Inc. (0001850266) (Filer)

      7/10/24 12:15:03 AM ET
      $AKLI
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 POS filed by Akili Inc.

      S-8 POS - Akili, Inc. (0001850266) (Filer)

      7/2/24 10:00:03 AM ET
      $AKLI
      Medical/Dental Instruments
      Health Care

    $AKLI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Large owner Puretech Health Plc

      4 - Akili, Inc. (0001850266) (Issuer)

      7/8/24 7:42:32 PM ET
      $AKLI
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Large owner Palihapitiya Chamath

      4 - Akili, Inc. (0001850266) (Issuer)

      7/5/24 5:36:39 PM ET
      $AKLI
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Large owner Temasek Holdings (Private) Ltd

      4 - Akili, Inc. (0001850266) (Issuer)

      7/5/24 11:54:03 AM ET
      $AKLI
      Medical/Dental Instruments
      Health Care